Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment

Published:2015-07 Issue:4 Volume:4 Page:380-382
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Barroso Bruno,Miquel Marie,Marasescu Raluca,Demasles Stéphanie,Krim Elsa,Bonnan Mikael

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference10 articles.

1. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone;Barkhof;Neurology,1992

2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy;Bloomgren;N Engl J Med,2012

3. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approches during the first year of natalizumab discontinuation;Capobianco;Eur J Neurol,2015

4. MS disease activity in RESTORE. A randomized 24-week natalizumab treatment interruption study;Fox;Neurology,2014

5. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group;Kappos;Lancet,1999

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natalizumab-associated PML;Neurology;2017-02-22

2. Editors’ Welcome;Multiple Sclerosis and Related Disorders;2015-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3